Andrea G. Cochran

Affiliations: 
1996- Genentech, Inc., San Francisco, CA, United States 
Area:
proteins, biophysics, biochemistry
Google:
"Andrea Cochran"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cochran AG, Conery AR, Sims RJ. (2019) Bromodomains: a new target class for drug development. Nature Reviews. Drug Discovery
Wang S, Tsui V, Crawford TD, et al. (2018) GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like. Journal of Medicinal Chemistry
Oppikofer M, Sagolla M, Haley B, et al. (2017) Non-canonical reader modules of BAZ1A promote recovery from DNA damage. Nature Communications. 8: 862
Oppikofer M, Bai T, Gan Y, et al. (2017) Expansion of the ISWI chromatin remodeler family with new active complexes. Embo Reports
Crawford TD, Audia JE, Bellon S, et al. (2017) GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2). Acs Medicinal Chemistry Letters. 8: 737-741
Crawford TD, Vartanian S, Côté A, et al. (2017) Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. Bioorganic & Medicinal Chemistry Letters
Crawford TD, Romero FA, Lai KW, et al. (2016) Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. Journal of Medicinal Chemistry
Crawford TD, Tsui V, Flynn EM, et al. (2016) Diving into the water: Inducible binding conformations for BRD4, TAF1(2), BRD9, and CECR2 bromodomains. Journal of Medicinal Chemistry
Vinogradova M, Gehling VS, Gustafson A, et al. (2016) An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nature Chemical Biology
Taylor AM, Côté A, Hewitt MC, et al. (2016) Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). Acs Medicinal Chemistry Letters. 7: 531-536
See more...